E. Aringhieri

Biography

Eugenio Aringhieri Chief Executive Officer Eugenio Aringhieri is CEO of the Dompé Group, an Italian biopharmaceutical company. Since 2007, in line with the wishes of its Shareholder, he has promoted the company’s functional reorganisation and given impetus to its industrial strategy with the aim of making the Group an internationally recognised science-based company. To this end, in 2008 he consolidated its partnership with Amgen by creating Amgen Dompé, an equal joint venture of which he was President, and established the strategic programme and priority objectives of Biogen Dompé, an equal joint venture - of which he was CEO - between Biogen Idec, the world’s leading biotech company, and Dompé, thus consolidating their initial marketing agreement into a partnership by creating a new company in Italy and Switzerland. With a focus on the value of innovation in research into biotechnological therapeutic solutions to global health problems, Aringhieri promotes an international approach based on the network. He was Vice-President of the Board of Directors of Philogen, an outstanding Italo-Swiss biotech company dedicated to developing products for the treatment of cancer, rheumatoid arthritis and certain eye diseases, of which Dompé is the majority shareholder. He joined the Board of Directors of AAA (Advanced Accelerator Applications), a leading company in the field of molecular medicine. In the same year, he became President and Managing Director of Anabasis, an Italian biotech company that develops innovative drugs based on rhNGF (the discovery of which led to Prof. Rita Levi Montalcini being awarded the Nobel Prize) for the treatment of serious eye diseases for which no effective therapy is currently available, whose acquisition was completed in February 2012. Aringhieri has also actively supported high-tech startups and since 2016 he has been a Member of the e-Novia Board of Directors, a company focused on fostering business innovation through international research projects and partnershaips. Eugenio Aringhieri Chief Executive Officer Eugenio Aringhieri is CEO of the Dompé Group, an Italian biopharmaceutical company. Since 2007, in line with the wishes of its Shareholder, he has promoted the company’s functional reorganisation and given impetus to its industrial strategy with the aim of making the Group an internationally recognised science-based company. To this end, in 2008 he consolidated its partnership with Amgen by creating Amgen Dompé, an equal joint venture of which he was President, and established the strategic programme and priority objectives of Biogen Dompé, an equal joint venture - of which he was CEO - between Biogen Idec, the world’s leading biotech company, and Dompé, thus consolidating their initial marketing agreement into a partnership by creating a new company in Italy and Switzerland. With a focus on the value of innovation in research into biotechnological therapeutic solutions to global health problems, Aringhieri promotes an international approach based on the network. He was Vice-President of the Board of Directors of Philogen, an outstanding Italo-Swiss biotech company dedicated to developing products for the treatment of cancer, rheumatoid arthritis and certain eye diseases, of which Dompé is the majority shareholder. He joined the Board of Directors of AAA (Advanced Accelerator Applications), a leading company in the field of molecular medicine. In the same year, he became President and Managing Director of Anabasis, an Italian biotech company that develops innovative drugs based on rhNGF (the discovery of which led to Prof. Rita Levi Montalcini being awarded the Nobel Prize) for the treatment of serious eye diseases for which no effective therapy is currently available, whose acquisition was completed in February 2012. Aringhieri has also actively supported high-tech startups and since 2016 he has been a Member of the e-Novia Board of Directors, a company focused on fostering business innovation through international research projects and partnershaips.

Research Interest

innovation in research into biotechnological therapeutic solutions  developing products for the treatment of cancer, rheumatoid arthritis and certain eye diseases